Value Set OID: 2.16.840.1.113883.3.464.1003.101.12.1008
Outpatient Consultation
Measure | Description |
---|---|
CMS1188v1 | Sexually Transmitted Infection (STI) Testing for People with HIV |
CMS135v10 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v11 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v12 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v5 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v6 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v7 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v8 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v9 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS136v10 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v11 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v12 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v13 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v6 | ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication |
CMS136v7 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v8 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v9 | Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS142v10 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v11 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v12 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v5 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v6 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v7 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v8 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v9 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS143v10 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v11 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v12 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v5 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v6 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v7 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v8 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v9 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS144v10 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v11 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v12 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v5 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v6 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v7 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v8 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v9 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS145v10 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v11 | Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ? 40%) |
CMS145v12 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <=40%) |
CMS145v5 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v6 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v7 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v8 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v9 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS146v10 | Appropriate Testing for Pharyngitis |
CMS146v11 | Appropriate Testing for Pharyngitis |
CMS146v12 | Appropriate Testing for Pharyngitis |
CMS146v8 | Appropriate Testing for Children with Pharyngitis |
CMS146v9 | Appropriate Testing for Pharyngitis |
CMS147v10 | Preventive Care and Screening: Influenza Immunization |
CMS147v11 | Preventive Care and Screening: Influenza Immunization |
CMS147v12 | Preventive Care and Screening: Influenza Immunization |
CMS147v6 | Preventive Care and Screening: Influenza Immunization |
CMS147v7 | Preventive Care and Screening: Influenza Immunization |
CMS147v8 | Preventive Care and Screening: Influenza Immunization |
CMS147v9 | Preventive Care and Screening: Influenza Immunization |
CMS149v10 | Dementia: Cognitive Assessment |
CMS149v11 | Dementia: Cognitive Assessment |
CMS149v12 | Dementia: Cognitive Assessment |
CMS149v5 | Dementia: Cognitive Assessment |
CMS149v6 | Dementia: Cognitive Assessment |
CMS149v7 | Dementia: Cognitive Assessment |
CMS149v8 | Dementia: Cognitive Assessment |
CMS154v10 | Appropriate Treatment for Upper Respiratory Infection (URI) |
CMS154v11 | Appropriate Treatment for Upper Respiratory Infection (URI) |
CMS154v12 | Appropriate Treatment for Upper Respiratory Infection (URI) |
CMS161v10 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v11 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v5 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v6 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v7 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v8 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS161v9 | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS167v5 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
CMS167v6 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
CMS177v10 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v11 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v12 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v5 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v6 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v7 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v8 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS177v9 | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
CMS249v1 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS249v2 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS249v3 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS249v4 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS249v5 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS249v6 | Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture |
CMS314v1 | HIV Viral Suppression |
CMS347v4 | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
CMS347v5 | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
CMS347v6 | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
CMS347v7 | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
CMS52v5 | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis |
CMS52v6 | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis |
CMS52v7 | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis |
CMS52v8 | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis |
CMS56v10 | Functional Status Assessment for Total Hip Replacement |
CMS56v11 | Functional Status Assessment for Total Hip Replacement |
CMS56v12 | Functional Status Assessment for Total Hip Replacement |
CMS56v5 | Functional Status Assessment for Total Hip Replacement |
CMS56v6 | Functional Status Assessment for Total Hip Replacement |
CMS56v7 | Functional Status Assessment for Total Hip Replacement |
CMS56v8 | Functional Status Assessment for Total Hip Replacement |
CMS56v9 | Functional Status Assessment for Total Hip Replacement |
CMS66v10 | Functional Status Assessment for Total Knee Replacement |
CMS66v5 | Functional Status Assessment for Total Knee Replacement |
CMS66v6 | Functional Status Assessment for Total Knee Replacement |
CMS66v7 | Functional Status Assessment for Total Knee Replacement |
CMS66v8 | Functional Status Assessment for Total Knee Replacement |
CMS66v9 | Functional Status Assessment for Total Knee Replacement |
CMS951v1 | Kidney Health Evaluation |
CMS951v2 | Kidney Health Evaluation |
MedicalCodify.com